Alongside its Q4 results, the company announced an increase of its Prime membership monthly fee from $12.99 to $14.99 and annual membership from $119 to $139.
The acquisition marks Hikma’s expansion into Canada and includes a portfolio of 25 sterile injectable products, three in-licensed ophthalmic products and a pipeline of seven additional products.
Nearly 30 generic drugmakers in Asia, Africa and the Middle East will make inexpensive versions of Merck’s COVID-19 pill molnupiravir, according to a report.
The bid for GSK’s assets, including Sensodyne toothpaste and Advil painkillers, comes as Unilever is dealing with steep inflation and sluggish growth in emerging markets.